ObjectiveTo observe the clinical efficacy and safety of Tangning Tongluo tablets in the treatment of nonproliferative diabetic retinopathy （DR）. MethodsFourteen research centers participated in this study， which spanned a time interval from September 2021 to May 2023. A total of 240 patients with nonproliferative DR were included and randomly assigned into an observation group （120 cases） and a control group （120 cases）. The observation group was treated with Tangning Tongluo tablets， and the control group with calcium dobesilate capsules. Both groups were treated for 24 consecutive weeks. The vision， DR progression rate， retinal microhemangioma， hemorrhage area， exudation area， glycosylated hemoglobin （HbA1c） level， and TCM syndrome score were assessed before and after treatment， and the safety was observed. ResultsThe vision changed in both groups after treatment （P<0.05）， and the observation group showed higher best corrected visual acuity （BCVA） than the control group （P<0.05）. The DR progression was slow with similar rates in the two groups. The fundus hemorrhage area and exudation area did not change significantly after treatment in both groups， while the observation group outperformed the control group in reducing the fundus hemorrhage area and exudation area. There was no significant difference in the number of microhemangiomas between the two groups before treatment. After treatment， the number of microhemangiomas decreased in both the observation group （Z=-1.437， P<0.05） and the control group （Z=-2.238， P<0.05）， and it showed no significant difference between the two groups. As the treatment time prolonged， the number of microhemangiomas gradually decreased in both groups. There was no significant difference in the HbA1c level between the two groups before treatment. After treatment， the decline in the HbA1c level showed no significant difference between the two groups. The TCM syndrome score did not have a statistically significant difference between the two groups before treatment. After treatment， neither the TCM syndrome score nor the response rate had significant difference between the two groups. With the extension of the treatment time， both groups showed amelioration of TCM syndrome compared with the baseline. ConclusionTangning Tongluo tablets are safe and effective in the treatment of nonproliferative DR， being capable of improving vision and reducing hemorrhage and exudation in the fundus.

Objective:To compare the prognostic value of two predictive models based on C-reactive protein(CRP)and albumin(ALB),namely the CRP to ALB ratio(CAR)and the Glasgow prognostic score(GPS),in newly diagnosed patients with diffuse large B-cell lymphoma(DLBCL).Methods:The data of newly diagnosed DLBCL patients admitted to our center from May 2014 to January 2022 were reviewed.A total of 111 patients who completed at least 4 cycles of R-CHOP or R-CHOP-like chemotherapy with detailed clinical,laboratory data and follow-up information were included.The receiver operating characteristic(ROC)curve was performed to evaluate the predictive value of pre-treatment CAR on disease progression and survival.Furthermore,the association between CAR and baseline clinical,laboratory characteristics of patients was evaluated,and progression-free survival(PFS)and overall survival(OS)were compared between different CAR and GPS subgroups.Finally,the univariate and multivariate COX propor-tional hazard regression models were used to analyze the factors affecting disease outcomes.Results:ROC curve showed that the area under the curve(AUC)of CAR predicting PFS and OS in DLBCL patients was 0.687(P=0.002)and 0.695(P=0.005),respectively,with the optimal cut-off value of 0.11 for both predicting PFS and OS.Compared with the lower CAR(＜0.11)group,the higher CAR(≥0.11)group had more clinical risk factors,including age＞60 years(P=0.025),ECOG score ≥2(P=0.004),Lugano stage Ⅲ-Ⅳ(P＜0.001),non-germinal center B-cell-like(non-GCB)subtype(P=0.035),elevated lactate dehydrogenase(LDH)(P＜0.001),extranodal involved site＞1(P=0.004)and IPI score＞2(P＜0.001).The interim response evaluation of patients showed that the overall response rate(ORR)and complete response rate(CRR)in the lower CAR group were both significantly better than those in the higher CAR group(ORR:96.9％vs 80.0％,P=0.035;CRR:63.6％vs 32.5％,P=0.008).With a median follow-up of 24 months,patients with lower CAR had significantly longer median PFS and OS than those with higher CAR(median PFS:not reached vs 67 months,P=0.0026;median OS:not reached vs 67 months,P=0.002),while there was no statistical difference in PFS(P=0.11)and OS(P=0.11)in patients with GPS of 0,1,and 2.Multivariate Cox regression analysis indicated that only sex(male)and IPI score＞2 were independent risk factors for both PFS and OS.Conclusion:CAR is significantly correlated with disease progression and survival in DLBCL patients;And compared with GPS,CAR has more advantages in predicting disease outcomes in DLBCL patients.

Objective:To compare the efficacy and safety of flumatinib (FM)and imatinib (IM)as first-line treatment in newly-diagnosed patients with chronic myeloid leukemia in chronic phase (CML-CP ) in real world. Methods:A total of 84 newly-diagnosed CP-CML patients in our center from December 2019 to December 2022 were retrospectively analyzed.Among them,32 cases received FM as first-line treatment,and 52 cases received IM. Molecular response (MR),disease progression,survival and incidence of adverse events (AEs)were compared between the two groups.Results:At 3 months of treatment,the incidences of early molecular response (EMR ),MR2.0 and MR3.0 were 96.7％,70.0％ and 20.0％ in FM group,respectively,which were significantly higher than 77.1％,29. 2％ and 0 in IM group (all P<0.05 ).At 6,9 and 12 months of treatment,the incidences of major molecular response (MMR)in FM group were 68.2％,85.7％ and 90.0％,respectively,which were significantly higher than 22.9％,34.0％ and 51.1％ in IM group (all P<0.01).The median time to achieve MMR in FM group was 6(6-9)months,which was significantly shorter than 18(12-22)months in IM group (P<0.001 ).The 3-year progression-free survival rate and 3-year event-free survival rate in FM group were 100％ and 68.8％,respectively,while in IM group were 98.1％ and 55.8％.There were no significant differences between the two groups (P>0.05). The incidence of grade 3-4 hematologic AEs in FM group was 21 .9％,which was slightly lower than 25.0％ in IM group,but the difference was not significant (P>0.05 ).Conclusion:In real clinical practice,FM as first-line treatment achieves MMR earlier than IM,and exhibits good safety profile in newly-diagnosed CML-CP patients,which potentially leads to improved long-term survival and treatment-free remission.

The main characteristics of neurodegenerative diseases represented by Alzheimer’s disease (AD) and Parkinson’s disease (PD) is the progressive irreversible loss of neurons, leading to varying degrees of pathological changes and loss of cognitive function. There is still no effective treatment. With the acceleration of global aging society, the incidence of neurodegenerative diseases is rapidly increasing, becoming a serious global public health concern that urgently requires the development of effective therapeutic strategies. The Hippo signaling pathway, a highly evolutionarily conserved pathway, consists of the core components MST1/2, LATS1/2, and downstream effectors, transcriptional co-activators YAP and TAZ. It plays a crucial role in the regulation of various biological processes such as cell proliferation, differentiation, development, and apoptosis. Dysregulation of the Hippo pathway contributes to the development of many diseases, including cancer, cardiovascular diseases, immune disorders, etc. Therefore, targeting the dysregulated components of the Hippo pathway may be an effective strategy for treating various diseases. Increasing evidence indicates that the Hippo pathway is excessively activated in the development of neurodegenerative diseases, manifested by increased expression of MST1 and downregulation of YAP. Stabilizing the Hippo pathway levels has shown improvements in AD and PD. However, most studies on the Hippo pathway in AD and PD focus on changes in the expression levels of Hippo pathway components, and research in other neurodegenerative diseases is still lacking. Therefore, further investigation is needed to fully understand the mechanistic role of the Hippo pathway in neurodegenerative diseases. Meanwhile, miRNA, similarly dysregulated in neurodegenerative diseases and serving as biomarkers, is a primary target for miRNA therapy in neurodegenerative diseases, including AD and PD. Activating or inhibiting dysregulated miRNAs is the main strategy of miRNA therapy during the neurodegenerative disease development. Evidence suggests that the interaction between the Hippo pathway and miRNA can result in widespread biological effects and crosstalk in the occurrence of different types of diseases. However, studies on the interplay between the Hippo pathway and miRNA in neurodegenerative diseases are relatively scarce. In this paper, we predicted the miRNAs related to Hippo pathway through bioinformatics database, and further screened the miRNAs with crosstalk relationship with Hippo signaling pathway through experiments in combination with PubMed. Then, the mechanism of action of Hippo signaling pathway related miRNAs in AD and PD is further elucidated. It is reported that the Hippo pathway and its related miRNA may exert neuroprotective effects by reducing oxidative stress, improving neuroinflammation, stabilizing autophagy levels, maintaining neuronal mitochondrial function, and ameliorating blood-brain barrier dysfunction, thereby delaying the progression of AD and PD. However, research on miRNA directly regulating the Hippo pathway to improve AD and PD is limited, and observations of the Hippo pathway and its related miRNA in other neurodegenerative diseases are scarce. However, considering the regulatory relationship between the Hippo pathway and miRNA in multiple diseases and their respective roles in key mechanisms of neurodegenerative diseases, such as oxidative stress and neuroinflammation, the crosstalk between miRNA and the Hippo pathway holds a crucial regulatory role in the development of neurodegenerative diseases. Thus, the interaction pathways of the Hippo pathway and its related miRNA may be a pivotal avenue for exploring effective therapeutic strategies for neurodegenerative diseases in the future.

Objective:In the context of the aging trend of China's population,it aims to analyze the trend of elderly disabled population growth in various regions and calculate the potential payment pressure of long-term care insurance for the disabled population,thereby providing policy implications for China's long-term care insurance system.Methods:A model for estimating the amount of expenditure on long-term care insurance fund was constructed,using the population age structure of each province in China from 2025 to 2060 obtained from the random forest model,and combining multi-source data such as the disability rate of the elderly population and the care cost of disabled elderly people to predict the number of elderly disabled people and the payment amount of long-term care insurance in each province in the future.Results:The aging trend in China will continue to intensify and exhibit a significant structural feature.The peak of the aging ratio in northeastern regions such as Inner Mongolia,Heilongjiang,Jilin,and Liaoning will come earliest,while the number of elderly people with disabilities in provinces with large populations such as Shandong,Sichuan,and Henan are relatively larger.Guangdong will have the largest number of disabled elderly people by 2055.Conclusion:It is suggested that the long-term care insurance system should be steadily advanced,with national-level support for the construction of the system in Northeast China and populous provinces.

Objective:In the context of the aging trend of China's population,it aims to analyze the trend of elderly disabled population growth in various regions and calculate the potential payment pressure of long-term care insurance for the disabled population,thereby providing policy implications for China's long-term care insurance system.Methods:A model for estimating the amount of expenditure on long-term care insurance fund was constructed,using the population age structure of each province in China from 2025 to 2060 obtained from the random forest model,and combining multi-source data such as the disability rate of the elderly population and the care cost of disabled elderly people to predict the number of elderly disabled people and the payment amount of long-term care insurance in each province in the future.Results:The aging trend in China will continue to intensify and exhibit a significant structural feature.The peak of the aging ratio in northeastern regions such as Inner Mongolia,Heilongjiang,Jilin,and Liaoning will come earliest,while the number of elderly people with disabilities in provinces with large populations such as Shandong,Sichuan,and Henan are relatively larger.Guangdong will have the largest number of disabled elderly people by 2055.Conclusion:It is suggested that the long-term care insurance system should be steadily advanced,with national-level support for the construction of the system in Northeast China and populous provinces.

Objective:In the context of the aging trend of China's population,it aims to analyze the trend of elderly disabled population growth in various regions and calculate the potential payment pressure of long-term care insurance for the disabled population,thereby providing policy implications for China's long-term care insurance system.Methods:A model for estimating the amount of expenditure on long-term care insurance fund was constructed,using the population age structure of each province in China from 2025 to 2060 obtained from the random forest model,and combining multi-source data such as the disability rate of the elderly population and the care cost of disabled elderly people to predict the number of elderly disabled people and the payment amount of long-term care insurance in each province in the future.Results:The aging trend in China will continue to intensify and exhibit a significant structural feature.The peak of the aging ratio in northeastern regions such as Inner Mongolia,Heilongjiang,Jilin,and Liaoning will come earliest,while the number of elderly people with disabilities in provinces with large populations such as Shandong,Sichuan,and Henan are relatively larger.Guangdong will have the largest number of disabled elderly people by 2055.Conclusion:It is suggested that the long-term care insurance system should be steadily advanced,with national-level support for the construction of the system in Northeast China and populous provinces.

Objective:In the context of the aging trend of China's population,it aims to analyze the trend of elderly disabled population growth in various regions and calculate the potential payment pressure of long-term care insurance for the disabled population,thereby providing policy implications for China's long-term care insurance system.Methods:A model for estimating the amount of expenditure on long-term care insurance fund was constructed,using the population age structure of each province in China from 2025 to 2060 obtained from the random forest model,and combining multi-source data such as the disability rate of the elderly population and the care cost of disabled elderly people to predict the number of elderly disabled people and the payment amount of long-term care insurance in each province in the future.Results:The aging trend in China will continue to intensify and exhibit a significant structural feature.The peak of the aging ratio in northeastern regions such as Inner Mongolia,Heilongjiang,Jilin,and Liaoning will come earliest,while the number of elderly people with disabilities in provinces with large populations such as Shandong,Sichuan,and Henan are relatively larger.Guangdong will have the largest number of disabled elderly people by 2055.Conclusion:It is suggested that the long-term care insurance system should be steadily advanced,with national-level support for the construction of the system in Northeast China and populous provinces.

Objective:In the context of the aging trend of China's population,it aims to analyze the trend of elderly disabled population growth in various regions and calculate the potential payment pressure of long-term care insurance for the disabled population,thereby providing policy implications for China's long-term care insurance system.Methods:A model for estimating the amount of expenditure on long-term care insurance fund was constructed,using the population age structure of each province in China from 2025 to 2060 obtained from the random forest model,and combining multi-source data such as the disability rate of the elderly population and the care cost of disabled elderly people to predict the number of elderly disabled people and the payment amount of long-term care insurance in each province in the future.Results:The aging trend in China will continue to intensify and exhibit a significant structural feature.The peak of the aging ratio in northeastern regions such as Inner Mongolia,Heilongjiang,Jilin,and Liaoning will come earliest,while the number of elderly people with disabilities in provinces with large populations such as Shandong,Sichuan,and Henan are relatively larger.Guangdong will have the largest number of disabled elderly people by 2055.Conclusion:It is suggested that the long-term care insurance system should be steadily advanced,with national-level support for the construction of the system in Northeast China and populous provinces.